Daily Roundup

PLS Group Ltd is firing on all cylinders. The lithium producer reported a record production quarter with 267.6 kilotonnes and sales of 223.6kt in September, translating to $563 million in revenue. More impressive than the headline numbers is what's happening behind the scenes—unit operating costs dropped to $539 per tonne, a significant achievement in an increasingly competitive market.

The company's cash generation tells the real story. With a cash margin from operations hitting $392 million and a cash balance of $2.2 billion sitting on the balance sheet, PLS is in enviable financial shape. That strength was reinforced by the completion of a $700 million Senior Unsecured Notes offering, giving the company serious firepower for what comes next.

Speaking of what's next, PLS inked a game-changing 20-year power purchase agreement with Fortescue, committing to supply 325 gigawatt-hours of electricity annually to the Pilgangoora operation. The deal is expected to shave another $15 to $20 per tonne off operating costs while dramatically cutting power-related emissions—potentially by up to 80 percent by 2030. For a company in a capital-intensive industry facing mounting pressure on both costs and carbon, this is a significant strategic win.

The company's ambitious P2000 Project, designed to double production capacity, has been approved, and PLS has revised its FY27 capital expenditure guidance to between $1.13 and $1.2 billion. Management expects to hit its full-year production targets of 1,030 to 1,100 kilotonnes, with unit operating costs (FOB) landing between $575 and $625 per tonne.

4DMedical is making serious inroads in respiratory imaging. The company landed a five-year contract with a major U.S. Veterans Affairs healthcare network to deploy its LDAi technology for COPD detection, and there's bipartisan congressional support for a pilot program using 4D functional lung imaging across the VA system. Meanwhile, SimonMed wrapped up a network-wide rollout of 4DMedical's CT:VQ technology across 125 U.S. imaging sites, and Stanford Medicine renewed its software agreement for the same platform.

The commercial momentum is translating into volume. 4DMedical hit a record quarterly scan volume of 119,672 scans, with its global install base now standing at 724 sites. Operating revenue climbed 66 percent year-over-year to $2.3 million in the quarter. With $242.8 million in cash, the company is well-positioned to accelerate product development and chase strategic opportunities.

SiteMinder, the hotel commerce platform, is leaning into artificial intelligence as a growth driver. The company's FY26 results marked a turning point—consistent performance, profitability, and meaningful AI integration across its platform. Management is projecting mid-20s compound annual growth rates for annual recurring revenue and adjusted EBITDA margin expansion through 2030, suggesting the company believes it's found the right formula for scaling profitably.

Aeeris Ltd is in the middle of a strategic reset. The company completed its exit from lower-margin, non-core reseller and climate-science contracts as part of its "New Dawn" strategy. While annual recurring revenue dipped 1.4 percent year-over-year, annual revenue per customer jumped 10 percent, signaling a deliberate shift toward higher-value enterprise relationships. Quarterly revenue came in at $975,191, up 10 percent quarter-over-quarter and 6.7 percent year-over-year. The transformation is self-funded with no new debt or equity raised, and the company maintained a debt-free balance sheet with $1.02 million in cash. Q2 marks the start of severe weather season, historically a strong period for the business.

Frasers Group and Accent Group are locked in a takeover battle. Frasers declared its offer price of A$0.65 per share as best and final, with the bid set to close on January 29, 2027. No competing proposals have emerged in the four months since the bid was announced. However, Accent Group's Independent Board Committee is having none of it, maintaining its recommendation that shareholders reject the offer. The committee argues Frasers is trying to gain influence over the board without paying a control premium—essentially trying to get a controlling stake on the cheap.